BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:18 PM
 | 
Jun 28, 2010
 |  BC Extra  |  Top Story

Linagliptin meets Phase III endpoints

Linagliptin met the primary endpoint in each of four Phase III trials to treat Type II diabetes, Boehringer Ingelheim GmbH (Ingelheim, Germany) said...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >